What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach

SIMPLE SUMMARY: The hypomethylating agents (HMA) azacitidine and decitabine are among the standard treatment options for myeloid neoplasms. However, the treatment of patients with myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML) who progress after treatment with HMA is chal...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, Hussein, Gurnari, Carmelo, Xie, Zhuoer, Bewersdorf, Jan Philipp, Zeidan, Amer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137017/
https://www.ncbi.nlm.nih.gov/pubmed/37190176
http://dx.doi.org/10.3390/cancers15082248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137017/
https://www.ncbi.nlm.nih.gov/pubmed/37190176
http://dx.doi.org/10.3390/cancers15082248

Ejemplares similares